Skip to content

Dr. Barry Dworkin

  • About
  • Radio Interviews
    • Wednesday House Call
    • Sunday House Call Shows
  • Articles
    • Health Headlines
    • Prevention and Screening
    • Clinical Research
    • Health Policy
    • Cancer/Oncology
    • Neurology
  • Phase 2 study with a long way to go suggests that a desert-toad-derived psychedelic drug in nasal spray format may provide relief for people with treatment-resistant depression.

    November 2, 2026

    Medical Mythbusting Commentary for November 2, 2026 Source:A fast-acting nasal spray offers hope for hard-to-treat depression: study Reference:Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression

  • New rapid five-day protocol application of transcranial magnetic stimulation brain for the treatment of treatment-resistant depression seems to be of equal efficacy of the standard six- week treatment cycle.

    February 26, 2026

    Medical Mythbusting Commentary for February 26, 2026 Source:New brain stimulation approach could treat depression in just 5 days Reference:Efficacy of 5 × 5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression. 

  • Facebook
  • X